Phase III Trial of Herceptin Hylecta or Phesgo with Chemotherapy for HER2 Positive Endometrial Cancer
A phase III trial is testing the efficacy of adding Herceptin Hylecta or Phesgo to standard chemotherapy in HER2 positive endometrial cancer.
Indication
Clinical and regulatory intelligence for HER2 Positive Endometrial Cancer with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.